Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Launch Date: October 31, 2024

Release Date: October 31, 2024

Expiration Date: September 30, 2025

FACULTY

Amy Armstrong, MD

Assistant Professor of Pediatrics

Division of Hematology/Oncology

Neurofibromatosis (NF) Center

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/neurofibromatosis-type-1-related-plexiform-neurofibromas-improving-diagnosis-and-monitoring-while-integrating-ongoing-updates-in-the-treatment-continuum-1

This is an accredited continuing education podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Launch Date: June 5, 2024

Release Date: June 5, 2024

Expiration Date: May 31, 2025

FACULTY BIO

Stephen Liu, MD

Associate Professor of Medicine

Director of Thoracic Oncology

Director of Developmental Therapeutics

Lombardi Comprehensive Cancer Center

Georgetown University

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/podcasts-in-nsclc-harboring-egfr-mutations-cutting-edge-reports-from-asco-2024

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Launch Date: May 30, 2024

Release Date: May 30, 2024

Expiration Date: April 30, 2025

FACULTY BIO

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology

Duke University

Tanya Dorff, MD

Professor of Medicine

City of Hope

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Launch Date: May 30, 2024

Release Date: May 30, 2024

Expiration Date: April 30, 2025

FACULTY BIO

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology

Duke University

Tanya Dorff, MD

Professor of Medicine

City of Hope

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Launch Date: May 30, 2024

Release Date: May 30, 2024

Expiration Date: April 30, 2025

FACULTY BIO

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology

Duke University

Tanya Dorff, MD

Professor of Medicine

City of Hope

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.

https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Launch Date: December 29, 2023

Release Date: December 29, 2023

Expiration Date: November 30, 2024

FACULTY BIOS

Benjamin Levy, MD

Associate Professor of Oncology

Johns Hopkins Medicine

Aaron Lisberg, MD

Assistant Professor of Clinical Medicine

University of California, Los Angeles

Alexander Spira, MD, PhD, FACP

Co-Director

Virginia Cancer Specialists Research Institute

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode

.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Launch Date: December 29, 2023

Release Date: December 29, 2023

Expiration Date: November 30, 2024

FACULTY BIOS

Benjamin Levy, MD

Associate Professor of Oncology

Johns Hopkins Medicine

Aaron Lisberg, MD

Assistant Professor of Clinical Medicine

University of California, Los Angeles

Alexander Spira, MD, PhD, FACP

Co-Director

Virginia Cancer Specialists Research Institute

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode

.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1